Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Landman

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
AIDS Research and Human Retroviruses|December 16, 2000
Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavirM Levacher, F Bouscarat, R Landman, et al.
HIV Clinical Trials|September 3, 2009
Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence) QuestionnaireB Spire, B Arnould, F Barbier, et al.
The New England Journal of Medicine|May 27, 1993
Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study GroupP M Girard, R Landman, C Gaudebout, et al.
Lancet (London, England)|June 17, 1989
Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patientsP M Girard, R Landman, C Gaudebout, et al.
The Journal of Antimicrobial Chemotherapy|June 10, 2021
Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infectionA Bachelard, V Isernia, D Vallois, et al.
The Journal of Antimicrobial Chemotherapy|February 29, 2012
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimensA G Marcelin, C Charpentier, M Wirden, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patientsXuejun Chen, Jack G Shi, Thomas Emm, et al.
Journal of Clinical Pharmacology|January 25, 2011
The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteersJack G Shi, Xuejun Chen, Ryan F McGee, et al.
Antimicrobial Agents and Chemotherapy|February 3, 2016
5-Azacytidine Enhances the Mutagenesis of HIV-1 by Reduction to 5-Aza-2'-DeoxycytidineJonathan M O Rawson, Michele B Daly, Jiashu Xie, et al.
Journal of Molecular Biology|May 16, 2017
Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and SpectraJonathan M O Rawson, Daryl M Gohl, Sean R Landman, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
AIDS Research and Human Retroviruses|December 16, 2000
Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavirM Levacher, F Bouscarat, R Landman, et al.
HIV Clinical Trials|September 3, 2009
Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence) QuestionnaireB Spire, B Arnould, F Barbier, et al.
The New England Journal of Medicine|May 27, 1993
Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study GroupP M Girard, R Landman, C Gaudebout, et al.
Lancet (London, England)|June 17, 1989
Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patientsP M Girard, R Landman, C Gaudebout, et al.
The Journal of Antimicrobial Chemotherapy|June 10, 2021
Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infectionA Bachelard, V Isernia, D Vallois, et al.
The Journal of Antimicrobial Chemotherapy|February 29, 2012
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimensA G Marcelin, C Charpentier, M Wirden, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patientsXuejun Chen, Jack G Shi, Thomas Emm, et al.
Journal of Clinical Pharmacology|January 25, 2011
The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteersJack G Shi, Xuejun Chen, Ryan F McGee, et al.
Antimicrobial Agents and Chemotherapy|February 3, 2016
5-Azacytidine Enhances the Mutagenesis of HIV-1 by Reduction to 5-Aza-2'-DeoxycytidineJonathan M O Rawson, Michele B Daly, Jiashu Xie, et al.
Journal of Molecular Biology|May 16, 2017
Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and SpectraJonathan M O Rawson, Daryl M Gohl, Sean R Landman, et al.
Pageof 5